Biotech Startups

Actithera develops a chemistry platform for targeted cancer treatment that optimizes radiation dose absorption in tumors while reducing exposure to healthy tissue, with flexibility to pair different radionuclides based on tumor characteristics.

5 investors

Adaptyx develops a minimally-invasive wearable dermal patch that continuously measures biomarkers in interstitial fluid using an array of programmable molecular switches. The continuous data feeds algorithms intended to help clinicians make timelier decisions and reduce avoidable complications and hospital readmissions, replacing traditional lab draws and repeat clinic visits.

5 investors

Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer. The company works on off-the-shelf immune cell therapies based on gamma delta 1 CAR T cell technology.

5 investors

Adient Medical develops absorbable medical devices, including implants designed to remain safe and effective during their useful lifetime and then dissolve on their own, avoiding removal procedures and related complications.

5 investors

Admit Therapeutics is a diagnostics and pharmaceutical company focused on neurological diseases, particularly Alzheimer's and dementia, leveraging AI/ML for biomarker analysis and clinical laboratory services. The company serves medical institutions and healthcare providers developing and deploying advanced diagnostic solutions.

5 investors

AdrenoMed AG is a clinical-stage biopharmaceutical company developing Enibarcimab (formerly Adrecizumab), a first-in-class antibody targeting the peptide Adrenomedullin to restore vascular integrity in critically ill patients, with septic shock as its lead indication. It applies a biomarker-guided precision medicine approach to identify patients most likely to benefit and is based in the Berlin area of Germany.

5 investors

Advemto maps complex cell function to genetic sequences at scale without requiring new laboratory instruments. The platform targets therapeutic development and TechBio companies seeking to accelerate preclinical validation of next-generation therapeutics.

5 investors

Aera Therapeutics develops genetic medicines using next-generation delivery technologies and precision payloads optimized for specific diseases. The company focuses on advancing transformative treatments in areas including oncology, rare genetic diseases, and cell therapies.

5 investors

Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease. The company serves eye care professionals and patients in the global ophthalmic pharmaceutical market.

5 investors

Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals. The company develops protective antibody therapeutics for hard-to-treat diseases, with an initial focus on neurodegenerative conditions and oncology.

5 investors

Alcolase is a biotech company developing science-based solutions for people with alcohol intolerance, a genetic condition affecting hundreds of millions of people, particularly in East Asia. It focuses on enzyme-based products to help those who experience adverse reactions to alcohol.

5 investors

Algen Biotechnologies discovers and develops small molecule therapeutics for cancer and inflammatory diseases using CRISPR, RNAi, and machine learning to decode functional gene networks and predict drug responses.

5 investors

Alixia develops therapeutics targeting tumor ecosystems to address cancer drug resistance and age-related diseases. The company integrates biology, biophysics, and computational chemistry to design compounds that disrupt metabolic and inflammatory triggers in multiple cell types within the tumor microenvironment.

5 investors

Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief. The company focuses on supporting patients through recovery following surgery.

5 investors

Alloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

5 investors

Allozymes develops custom enzymes using high-throughput experimentation combined with AI-guided design for enzyme engineering and biocatalysis. It applies these engineered enzymes to industrial and scientific applications.

5 investors

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

5 investors

Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University. Based in New Haven, CT.

5 investors

Altis Labs provides a web-based platform that applies AI models to medical imaging data to generate reproducible predictions and quantifications for clinical trials. It serves biopharma and clinical trial teams, helping them detect treatment effects, inform trial design and go/no-go decisions, and generate evidence for reimbursement.

5 investors

Altos Labs develops computational and scientific approaches to reverse disease through breakthrough medicines, operating research institutes focused on cell health, computation, and drug discovery.

5 investors

AltrixBio develops AJN003, a once-daily oral therapy that forms a temporary, non-systemic coating on the stomach and upper gastrointestinal tract to alter nutrient sensing and trigger metabolic and hormonal responses. The platform targets type 2 diabetes and obesity, with potential applications in oral drug delivery.

5 investors

AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells. It partners with pharmaceutical companies to co-develop products across applications including post-surgical non-opioid pain management and oncology.

5 investors

Amarin Corporation is a cardiovascular health pharmaceutical company developing treatments to prevent cardiovascular disease. The company focuses on pharmaceutical development and clinical research in the cardiovascular health sector.

5 investors

Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.

5 investors